摘要
目的:分析对比阿立哌唑与利培酮治疗精神分裂症的临床疗效及安全性。方法:将我院收治的80例精神分裂症患者随机分为研究组与对照组。研究组采用阿立哌唑治疗,对照组采用利培酮治疗。治疗2个周期(16周)后,观察对比2组临床疗效及药物不良反应。结果:研究组治疗的总有效率为87.50%,显著高于对照组的67.50%(P<0.05);研究组的不良反应主要表现为嗜睡,而对照组则以锥体外系反应为主,研究组不良反应发生率显著低于对照组(P<0.05)。结论:相较于利培酮,阿立哌唑治疗精神分裂的疗效更为确切,且不良反应轻微,是治疗精神分裂症的理想药物,适于推广。
Objective： To analyze and compare the clinical curative effect and safety of aripiprazole and risperidone in the treatment of schizophrenia. Methods： Eighty cases of schizophrenia treated in our hospital were equally divided into research group and control group. The patients in the research group were treated with aripiprazole,and those in the control group were treated with risperidone. After 2 cycles（ 16 weeks）,the clinical curative effect and drug adverse reactions between the two groups were observed and compared. Results： Total effective rate of the research group（ 87. 50%） was significantly higher than that of the control group（ 67. 50%,P 0. 05）; adverse reaction of the research group mainly involved drowsiness,and the patients of the control group mainly had extrapyramidal symptoms; the incidence of adverse reaction in the research group was significantly lower than that in the control group（ P 0. 05）. Conclusion： Compared with risperidone,aripiprazole exhibits more exact curative effect in the treatment of schizophrenia and mild adverse reaction. It is an ideal drug to treat schizophrenia and worthy of promotion.
出处
《现代临床医学》
2016年第4期262-263,共2页
Journal of Modern Clinical Medicine
